Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice

Journal of Alzheimer's Disease

Volumn 22, Issue 2, 2010, Pages 469-482

  Arbel Ornath, Michal ^a   Becker, Maria ^a   Rabinovich Toidman, Polina ^a   Gartner, Myra ^a   Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; amyloid ; A PP site; immunotherapy; intracellular A ; monoclonal antibodies; secretase

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA ACTIN; BETA SECRETASE 1; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOPROTEIN P 15095; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BBS1; PLACEBO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; BRAIN REGION; CELL DEATH; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SYSTEMIC THERAPY; TRANSGENIC MOUSE;

EID: 78650825703     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100753     Document Type: Article

References (52)

1. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890.
2. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82, 4245-4249.
3. Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181193.
4. Weksler ME, Gouras G, Relkin NR, Szabo P (2005) The immune system, amyloid-beta peptide, and Alzheimer's disease. ImmunolRev 205, 244-256.
5. Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, De Strooper B, Seed B (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACEJ Biol Chem 278, 48713-48719.
6. Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y (2001) Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci USA 98, 13554-13559.
7. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the beta-secretase BACEScience 314, 664-666.
8. Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K, Paganetti P, Mathews PM, Harroch S, Buxbaum JD (2004) BACE (beta-secretase) modulates the processing of APLP2 in vivo. Mol Cell Neurosci 25, 642-649.
9. Arbel M, Yacoby I, Solomon B (2005) Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci USA 102, 7718-7723.
10. Arbel M (2008) in Molecular Microbiology and Biotechnology (Tel-Aviv university, Tel-Aviv), p. 166.
11. Solomon B, Arbel-Ornath M, Peters-Libeu C, Varghese J (2010) Future strategies for development of novel BACE inhibitors: anti APP beta-site antibody and APP binding small molecule approaches for Alzheimer's disease In BACE: lead target for orchestrated therapy of Alzheimer's disease. John V, ed. John Wiley and sons, Inc., pp. 217-234.
12. Moechars D, Gilis M, Kuiperi C, Laenen I, Van Leuven F (1998) Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs. Neuroreport 9, 35613564.
13. Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F (2000) Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp Gerontol 35, 831-841.
14. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ (2009) A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. ArchNeurol 66, 190-199.
15. Christensen DZ, Kraus SL, Flohr A, Cotel MC, Wirths O, Bayer TA (2008) Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol 116, 647-655.
16. Arispe N, Pollard HB, Rojas E (1993) Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein A beta P-(1-40). in bilayer membranes. Proc Natl Acad Sci USA 90, 10573-10577.
17. Arispe N, Pollard HB, Rojas E (1994) The ability of amyloid beta-protein A beta P (1-40). to form Ca2+ channels provides a mechanism for neuronal death in Alzheimer's disease. Ann NY Acad Sci 747, 256-266.
18. Laferla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8, 499-509.
19. Eng LF, Ghirnikar RS (1994) GFAP and astrogliosis. Brain Pathol 4, 229-237.
20. Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, Lokensgard JR, Peterson PK (2004) Role of microglia in central nervous system infections. Clin Microbiol Rev 17, 942-964.
21. Ling EA, Wong WC (1993) The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia 7, 9-18.
22. Schwarz M, Nordt T, Bode C, Peter K (2002) The GP IIb/IIIa inhibitor a bciximab (c7E3) inhibits the binding of various lig-ands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaM-beta2). Thromb Res 107, 121-128.
23. Gonzalez-Scarano F, Baltuch G (1999) Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22, 219-240.
24. Ennaceur A, Delacour J (1988) A new one-trial test for neu-robiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31, 47-59.
25. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
26. Solomon B, Koppel R, Hanan E, Katzav T (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA 93, 452-455.
27. Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94, 4109-4112.
28. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoen-cephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54.
29. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65, 1031-1038.
30. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
31. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1, 1291-1296.
32. Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS (1996) Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. J Biol Chem 271, 9390-9397.
33. Arbel M, Solomon B (2007) A Novel immunotherapy for alzheimer's disease: antibodies against the beta-secretase cleavage site of APP Curr Alzheimer Res 4, 437-445.
34. Rakover I, Arbel M, Solomon B (2007) Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice with out a significant effect on brain Abeta levels. Neurodegener Dis 4, 392-402.
35. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity ofamyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 720-724.
36. Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, Hyman BT (2001) Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci 21, 858-864.
37. Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR (2005) Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoSMed 2, e355.
38. KawaharaM, Arispe N, Kuroda Y, Rojas E (1997) Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hy-pothalamic neurons. Biophys J 73, 67-75.
39. Rhee SK, Quist AP, Lal R (1998) Amyloid beta protein-(1-42) forms calcium-permeable, Zn2+-sensitive channel. J Biol Chem 273, 13379-13382.
40. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866.
41. Gouras GK, Almeida CG, Takahashi RH (2005) Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 26, 1235-1244.
42. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15-20.
43. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yam-aguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) In-traneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161, 1869-1879.
44. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 1012910140.
45. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
46. Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK (2007) Internalized antibodies to the Abe-ta domain of APP reduce neuronal Abeta and protect against synaptic alterations. JBiol Chem 282, 18895-18906.
47. Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amy-loidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160, 113-123.
48. Kim ML, Zhang B, Mills IP, Milla ME, Brunden KR, Lee VM (2008) Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci 28, 12052-12061.
49. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH (2002). The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22, 1858-1867.
50. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O (2004) Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55, 801-814.
51. Cataldo AM, Barnett JL, Pieroni C, Nixon RA (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism ofincreased beta-amyloidogenesis. J Neurosci 17, 6142-6151.
52. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellen-berg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2, 864-870.